Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovidâs most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). Source
No articles found.
We are a vertically integrated commercial biopharmaceutical company that develops,...
We are a vertically integrated commercial bioph...
Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committ...
Proteostasis Therapeutics, Inc. is an innovativ...
Eiger is a late stage biopharmaceutical company focused on the development and com...
Eiger is a late stage biopharmaceutical company...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.